drugset
drugset / Trial / NCT05200793

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

NCT05200793 ↗

Phase 4 Unknown 75 enrolled Alexandria University
RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).

Timeline

Start
2021-12-07
Primary completion
2022-07-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule 25 mg Oral
Comparator Linagliptin Small molecule 10 mg Oral
Comparator Metformin Small molecule 1500 mg Oral

Indications

polycystic ovary syndrome